A 68-year-old male with a 50 pack-year smoking history presents with progressive dyspnea and a dry cough over 6 months. HRCT chest shows upper-lobe centrilobular emphysema with lower-lobe subpleural reticulation and honeycombing consistent with usual interstitial pneumonia (UIP) pattern. Spirometry reveals FEV1 78% predicted, FVC 82% predicted, FEV1/FVC ratio 0.72, and DLCO 32% predicted. The combination of imaging findings and this distinctive PFT pattern is consistent with combined pulmonary fibrosis and emphysema (CPFE). Which of the following management approaches marked as **A** in the diagram represents the most appropriate initial step in the management of this patient?
A. Immediate referral for lung volume reduction surgery to relieve hyperinflation
B. High-dose oral corticosteroids as monotherapy to suppress inflammation
C. Smoking cessation and pulmonary hypertension screening with echocardiography
D. Inhaled long-acting beta-agonists alone to improve airflow obstruction
Explanation
Why smoking cessation and pulmonary hypertension screening with echocardiography is right
CPFE is a distinct syndrome affecting predominantly heavy smokers (>40 pack-years) with coexistent upper-lobe emphysema and lower-lobe UIP-pattern fibrosis. Smoking cessation is the mainstay of management and the single most impactful intervention to halt disease progression. Additionally, pulmonary hypertension occurs in 47–90% of CPFE cases and is often disproportionate to PFT abnormalities, making echocardiographic screening essential for risk stratification and guiding further investigation (RHC if estimated PASP >50 mmHg). These two interventions—cessation and PH screening—form the cornerstone of initial CPFE management per Cottin et al. (2005) and Harrison's 21st edition.
Why each distractor is wrong
High-dose oral corticosteroids as monotherapy: Corticosteroids have no proven role in CPFE management and may worsen outcomes in the presence of emphysema. They are not indicated as first-line therapy and do not address the underlying smoking-related pathology.
Inhaled long-acting beta-agonists alone: While bronchodilators may provide symptomatic relief, they do not address the fundamental pathophysiology of CPFE, do not halt fibrosis progression, and are insufficient as monotherapy. They are adjunctive at best.
Immediate referral for lung volume reduction surgery: LVRS is not a first-line intervention in CPFE. It may be considered in selected cases with severe emphysema and appropriate physiology, but it is premature before establishing smoking cessation, assessing PH status, and optimizing medical therapy.
High-YieldNEET PG
In CPFE, the pseudo-normal spirometry (preserved FEV1/FVC and TLC due to offsetting emphysema and fibrosis) masks severe disease; the disproportionately low DLCO (<40% predicted) and high PH prevalence are the true markers of severity. Smoking cessation + PH screening = first-line management.
Cottin V et al. Eur Respir J 2005; Harrison's Principles of Internal Medicine, 21st ed
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
